Tumor Biology

, Volume 35, Issue 1, pp 773–777 | Cite as

RETRACTED ARTICLE: Association between glutathione S-transferase M1 null variant and risk of bladder cancer in Chinese Han population

  • Wei Xu
  • Fa Wang
  • Li Ying
  • Hong-Hui Wang
Research Article


Glutathione S-transferase M1 (GSTM1) is one of the most important families of phase II isoenzymes known to detoxify a variety of electrophilic compounds and carcinogens. The GSTM1 null variant is associated with decreased enzyme activity, and it has been assumed to be associated with bladder cancer. The association between the GSTM1 null variant and bladder cancer in the Chinese Han population was unclear owing to the obvious inconsistency from published studies. To quantify the association between the GSTM1 null variant and bladder cancer in the Chinese Han population, we carried out the meta-analysis. We estimated the pooled odds ratio (OR) with its 95 % confidence interval (95 % CI) to assess the association. Eight studies with a total of 3,887 individuals were finally included into the meta-analysis. Overall, there was an obvious association between the GSTM1 null variant and risk of bladder cancer in the Chinese Han population (OR = 1.61, 95 % CI 1.41–1.84, P < 0.001). There was no heterogeneity across those eight studies (I 2 = 0 %). The cumulative meta-analyses showed a trend of more obvious association between the GSTM1 null variant and risk of bladder cancer in the Chinese Han population as data accumulated by year. There was no obvious evidence of publication bias in the meta-analysis. In conclusion, the GSTM1 null variant is significantly associated with risk of bladder cancer in the Chinese Han population.


Bladder cancer Glutathione S-transferase M1 Meta-analysis 


Conflicts of interest



  1. 1.
    Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251–85.CrossRefPubMedGoogle Scholar
  4. 4.
    Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60:244–72.CrossRefPubMedGoogle Scholar
  5. 5.
    Schmitz-Drager BJ. Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications. Eur Urol. 2011;60:721–3.CrossRefPubMedGoogle Scholar
  6. 6.
    Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423–36.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154–66.CrossRefPubMedGoogle Scholar
  11. 11.
    Srivastava DS, Mishra DK, Mandhani A, Mittal B, Kumar A, Mittal RD. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol. 2005;48:339–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Hao G, Xu C, Zhang H, Ge N, Meng Y, Yang M. GSTM1 genetic polymorphism and bladder cancer susceptibility [article in Chinese]. Chinese J Urol. 2002;23:344–6.Google Scholar
  13. 13.
    Ma QW, Lin GF, Chen JG, Shen JH. Polymorphism of glutathione S-transferase T1, M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer. Biomed Environ Sci. 2002;15:253–60.PubMedGoogle Scholar
  14. 14.
    Shao J, Gu M, Zhang Z, Xu Z, Hu Q, Qian L. Genetic variants of the cytochrome p450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population. Int J Urol. 2008;15:216–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP. Association of NAT2, GSTM1, GSTT1, CYP2A6, AND CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev. 2009;32:416–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Cash HL, Tao L, Yuan JM, Marsit CJ, Houseman EA, Xiang YB, et al. Line-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese. Int J Cancer. 2012;130:1151–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  19. 19.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  20. 20.
    Muellerleile P, Mullen B. Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health. 2006;96:515–22.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shao C, Xiang Y, Zhang W, Fang R, Cheng J. Polymorphisms of GSTM1 and GSTT1 with smoking and bladder cancer risk: a population-based case control study [article in Chinese]. Tumor. 2006;26:346–51.Google Scholar
  23. 23.
    Shao JF, Qian L, Wu H, Gu M, Hua L, Zhou J, et al. Genetic polymorphisms of GSTM1 and susceptibility to bladder cancer [article in Chinese]. Tumor. 2006;26:352–4.Google Scholar
  24. 24.
    Fu J, Yang Y, Chen B (2009) CYP1A1, NQO1, EPHX1 and GSTS gene polymorphism and bladder cancer susceptibility [article in Chinese]. Wanfang doctoral dissertationGoogle Scholar
  25. 25.
    Wang Z, Xue L, Chong T, Li H, Chen H. Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk. Tumour Biol. 2013;34:1651–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2013;34:973–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Mimic-Oka J. Glutathione S-transferases in kidney and urinary bladder tumors. Nat Rev Urol. 2009;6:281–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhu Y, He Q, Wang J, Pan HF. The association between GSTM1 polymorphism and gastric cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:685–91.CrossRefPubMedGoogle Scholar
  30. 30.
    Kumar V, Murthy AK, Suresh KP. Glutathione S-transferase M1 and T1 status and the risk of laryngeal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011;12:2221–6.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of Interventional Radiologythe Second Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations